PT88564A - Process for preparing a sustained release etodolac dosage form - Google Patents

Process for preparing a sustained release etodolac dosage form

Info

Publication number
PT88564A
PT88564A PT88564A PT8856488A PT88564A PT 88564 A PT88564 A PT 88564A PT 88564 A PT88564 A PT 88564A PT 8856488 A PT8856488 A PT 8856488A PT 88564 A PT88564 A PT 88564A
Authority
PT
Portugal
Prior art keywords
dosage form
sustained release
etodolac
preparing
weight
Prior art date
Application number
PT88564A
Other languages
English (en)
Other versions
PT88564B (pt
Inventor
John Joseph Michelucci
Deborah Marie Sherman
Richard Jay Deneale
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of PT88564A publication Critical patent/PT88564A/pt
Publication of PT88564B publication Critical patent/PT88564B/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
PT88564A 1987-09-24 1988-09-21 Processo para a preparacao de uma forma de dosagem de etodolac de libertacao retardada PT88564B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10050187A 1987-09-24 1987-09-24

Publications (2)

Publication Number Publication Date
PT88564A true PT88564A (pt) 1988-10-01
PT88564B PT88564B (pt) 1992-11-30

Family

ID=22280080

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88564A PT88564B (pt) 1987-09-24 1988-09-21 Processo para a preparacao de uma forma de dosagem de etodolac de libertacao retardada

Country Status (21)

Country Link
US (1) US4966768A (pt)
EP (1) EP0309157B1 (pt)
JP (1) JP2879061B2 (pt)
KR (1) KR960009410B1 (pt)
AT (1) ATE62132T1 (pt)
AU (1) AU613663B2 (pt)
CA (1) CA1318600C (pt)
DE (1) DE3862272D1 (pt)
DK (1) DK168421B1 (pt)
ES (1) ES2021838B3 (pt)
FI (1) FI89005C (pt)
GB (1) GB2209940B (pt)
GR (1) GR3001739T3 (pt)
HK (1) HK41994A (pt)
HU (1) HU200920B (pt)
IE (1) IE60311B1 (pt)
IL (1) IL87757A (pt)
MX (1) MX171463B (pt)
PH (1) PH26146A (pt)
PT (1) PT88564B (pt)
ZA (1) ZA887162B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993017673A1 (en) * 1992-03-03 1993-09-16 Top Gold Pty., Limited Sustained release analgesics
US5314697A (en) * 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
IN182040B (pt) * 1995-06-13 1998-12-12 American Home Prod
PE57198A1 (es) 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US20060068001A1 (en) * 1996-03-25 2006-03-30 Wyeth Extended release formulation
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US20030215507A1 (en) * 1996-03-25 2003-11-20 Wyeth Extended release formulation
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
EP1137403B1 (en) 1998-12-11 2009-03-11 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US7151100B1 (en) * 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
IN190974B (pt) * 1999-09-10 2003-09-06 Ranbaxy Lab Ltd
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
WO2003026687A1 (en) * 2001-09-28 2003-04-03 Nutraceutix, Inc. Delivery system for biological component
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
IL161491A0 (en) * 2001-11-07 2004-09-27 Synthon Bv Tamsulosin tablets
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
AU2003202550A1 (en) * 2002-01-09 2003-07-24 Ucb, S.A. Pharmaceutical formulations with modified release
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
AU2003295336A1 (en) * 2002-09-19 2004-04-08 Dennis A. Carson Use of etodoclac to treat hyperplasia
US6703044B1 (en) 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5457830B2 (ja) 2006-04-03 2014-04-02 オディディ,イサ オルガノゾル被膜を含む制御放出送達デバイス
PL2010158T3 (pl) * 2006-04-26 2016-09-30 Formulacje o kontrolowanym uwalnianiu zawierające niepowlekaną odrębną jednostkę(-i) i macierz o przedłużonym uwalnianiu
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007131804A1 (en) 2006-05-17 2007-11-22 Synthon B.V. Tablet composition with a prolonged release of tamsulosin
US8465770B2 (en) 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
TR200908308A1 (tr) 2010-01-18 2011-08-22 Turgut İlaçlari A.Ş. Etodolak içeren sürekli salım tablet formulasyonu
CN102485215B (zh) * 2010-12-03 2013-05-15 沈阳药科大学 依托度酸定时释药微丸制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3939178A (en) * 1971-06-01 1976-02-17 American Home Products Corporation Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4533551A (en) * 1984-02-17 1985-08-06 American Home Products Corporation Method of treating arthritis with etodolac
US4657757A (en) * 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate

Also Published As

Publication number Publication date
ZA887162B (en) 1990-05-30
FI884245A (fi) 1989-03-25
EP0309157A1 (en) 1989-03-29
ES2021838B3 (es) 1991-11-16
HUT50631A (en) 1990-03-28
GB8821749D0 (en) 1988-10-19
DE3862272D1 (de) 1991-05-08
DK168421B1 (da) 1994-03-28
JP2879061B2 (ja) 1999-04-05
FI884245A0 (fi) 1988-09-15
HU200920B (en) 1990-09-28
IL87757A (en) 1992-06-21
MX171463B (es) 1993-10-28
PT88564B (pt) 1992-11-30
CA1318600C (en) 1993-06-01
AU613663B2 (en) 1991-08-08
DK531088A (da) 1989-03-25
US4966768A (en) 1990-10-30
IL87757A0 (en) 1989-02-28
KR960009410B1 (en) 1996-07-19
ATE62132T1 (de) 1991-04-15
GR3001739T3 (en) 1992-11-23
HK41994A (en) 1994-05-06
PH26146A (en) 1992-03-18
GB2209940A (en) 1989-06-01
KR890004686A (ko) 1989-05-09
DK531088D0 (da) 1988-09-23
FI89005B (fi) 1993-04-30
AU2215388A (en) 1989-05-11
IE60311B1 (en) 1994-06-29
FI89005C (fi) 1993-08-10
EP0309157B1 (en) 1991-04-03
GB2209940B (en) 1991-08-14
JPH02270820A (ja) 1990-11-05
IE882709L (en) 1989-03-24

Similar Documents

Publication Publication Date Title
PT88564A (pt) Process for preparing a sustained release etodolac dosage form
SE8207167D0 (sv) Metod for framstellning av terapeutiska foreningar med forlengd utlosningstid baserade pa hydroxypropylmetylcellulosa
CA2127111A1 (en) A Method for Preparing Enteric-Coated Oral Drugs Containing Acid-Unstable Compounds
SE8301579D0 (sv) Metod for preparering av terapeutiska foreningar med vidmakthallande utlosning, baserade pa hydroxypropylmetylcellulosa med hog molekyler vikt
EP0525389A3 (en) Process for preparing mechanically stable, well disintegrating tablets from small active agent containing solid forms
SE8406081D0 (sv) Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
NZ234143A (en) Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
SE8104974L (sv) Suspension av mikrokapslad bakampicillin-syraadditionssalt for oral administration, i synnerhet pa barn
KR890009376A (ko) 분무 건조된 이부프로펜
MY103850A (en) Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them.
GB1360180A (en) Anthelmintically active benzimidazole derivatives and process for preparing them
PT85591A (en) Process for the preparation of multiple unit dosage pharmaceutical compositions comprising as a pharmaceutilly active compound l-dopa
NO307594B1 (no) Fremgangsmåte for fremstilling av en tørr, hydratisert cefalosporinpulverformulering, og farmsøytisk preparat
ATE65402T1 (de) Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
FI894899A0 (fi) Menetelmä dispergoituvan kiinteän lääkeainekoostumuksen valmistamiseksi
ES8307098A1 (es) Un procedimiento para la preparacion de un nuevo antitrombosico a base de oligosacaridos y polisacaridos.
ES2008604A6 (es) Procedimiento de preparar aditivos para productos ingeribles y aditivo correspondiente.
EP0521310A3 (en) Solid dispersion tablets containing 1,4-dihydropyridine derivatives and process for the preparation thereof
ATE55250T1 (de) Ifosfamid-lyophilisat und verfahren zu dessen herstellung.
HU895391D0 (en) Process for the preparation of novelnitroxy-alkyl-amine derivatives and pharmaceutical compositions containing said compounds
EP0285871A3 (en) Sustained release granulate without binding agent
PT84399A (en) Process for the preparation of pharmaceutical compositions containing sodium 2-(2,6-dichloroanilino) phenylacetate
IL67000A0 (en) 3-chloropregnane derivatives,their preparation and pharmaceutical compositions containing them
BG60697B2 (en) Medicamentous form having continous release based on ethodolacquer
ES8300747A1 (es) Procedimiento para la preparacion de derivados de acido in- dolacetico

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19920521

PC3A Transfer or assignment

Free format text: WYETH US

Effective date: 20030122

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20080921